Valuation: LivaNova PLC

Market Cap 412.82Cr 368.85Cr 344.13Cr 312.58Cr 588.7Cr 40TCr 593.09Cr 4.14TCr 1.62TCr 20TCr 1.55TCr 1.52TCr 65TCr P/E 2026 *
18.7x
P/E 2027 * 22.6x
Enterprise Value 420.32Cr 375.55Cr 350.38Cr 318.25Cr 599.39Cr 41TCr 603.87Cr 4.21TCr 1.64TCr 21TCr 1.58TCr 1.54TCr 66TCr EV / Sales 2026 *
2.76x
EV / Sales 2027 * 2.48x
Free-Float
98.6%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 01/03/2024
Director of Finance/CFO 56 31/10/2020
Investor Relations Contact - 01/08/2022
Director TitleAgeSince
Director/Board Member 69 19/10/2015
Chairman 74 09/06/2021
Director/Board Member 62 18/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.64% - - 412.82Cr
+0.94%+0.16%-25.58%+2.30% 17TCr
-1.38%-0.52%-12.70%+14.26% 11TCr
-0.26%+0.67%-24.92%+3.91% 11TCr
-0.03%+0.72%-46.94%-10.20% 7.6TCr
+0.59%+6.00%+3.10%+70.94% 6.04TCr
-0.65%+6.59%+11.44%+66.40% 5.35TCr
+0.10%+0.75%-6.33%-32.15% 4.91TCr
-1.21%-3.08%-19.32%+14.44% 4.06TCr
+1.43%-2.23%+27.77%+1.53% 3.15TCr
Average -0.05%+0.25%-10.39%+14.60% 7.77TCr
Weighted average by Cap. -0.04%-0.04%-16.32%+12.18%

Financials

2026 *2027 *
Net sales 152.2Cr 135.99Cr 126.88Cr 115.24Cr 217.05Cr 15TCr 218.67Cr 1.52TCr 595.66Cr 7.49TCr 571.4Cr 559.04Cr 24TCr 163.02Cr 145.66Cr 135.89Cr 123.43Cr 232.47Cr 16TCr 234.21Cr 1.63TCr 637.99Cr 8.02TCr 612Cr 598.77Cr 26TCr
Net income 23Cr 20Cr 19Cr 17Cr 32Cr 2.19TCr 33Cr 226.64Cr 89Cr 1.11TCr 85Cr 83Cr 3.58TCr 19Cr 17Cr 16Cr 14Cr 27Cr 1.81TCr 27Cr 187.24Cr 73Cr 919.57Cr 70Cr 69Cr 2.96TCr
Net Debt 7.5Cr 6.7Cr 6.25Cr 5.68Cr 11Cr 725.51Cr 11Cr 75Cr 29Cr 368.98Cr 28Cr 28Cr 1.19TCr -8.5Cr -7.59Cr -7.09Cr -6.44Cr -12Cr -822.25Cr -12Cr -85Cr -33Cr -418.17Cr -32Cr -31Cr -1.34TCr
Logo LivaNova PLC
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - LivaNova PLC